SciSparc Ltd. and Clearmind Medicine Inc. have collaborated to publish an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy targeting obesity and high blood sugar. The patent application, published under the European Patent Office, includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA). This combination therapy aims to treat metabolic syndrome, characterized by conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels. Metabolic syndrome affects up to one-third of U.S. adults and increases the risk of heart disease, stroke, obesity, and type 2 diabetes. The combination leverages PEA's anti-inflammatory and neuroprotective properties alongside MEAI's pharmacological profile to potentially offer safe and effective treatment for these health challenges. The patent publication marks a significant milestone in the collaboration, which has resulted in the filing of 13 patent families across jurisdictions including the United States, Europe, and China. The collaboration focuses on developing innovative therapies combining neuroplastogens and N-acylethanolamines, aiming to address mental health disorders, addiction, and metabolic conditions. SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism. Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics for underserved health problems like alcohol use disorder. The collaboration between SciSparc and Clearmind has led to significant intellectual property developments, including patents and potential treatments for widespread health challenges.

SciSparc-Clearmind Collaboration Leads to Publication of

SciSparc Ltd. and Clearmind Medicine Inc. have collaborated to publish an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy targeting obesity and high blood sugar. The patent application includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA), aiming to treat metabolic syndrome. The collaboration has resulted in 13 patent families across the United States, Europe, and China, focusing on therapies combining neuroplastogens and N-acylethanolamines.